Hibergene Revenue and Competitors
Estimated Revenue & Valuation
- Hibergene's estimated annual revenue is currently $2.3M per year.
- Hibergene's estimated revenue per employee is $162,000
Employee Data
- Hibergene has 14 Employees.
- Hibergene grew their employee count by -55% last year.
Hibergene's People
Name | Title | Email/Phone |
---|
Hibergene Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $54.4M | 183 | 6% | N/A | N/A |
#2 | $18M | 74 | -4% | N/A | N/A |
#3 | $162.7M | 482 | 39% | N/A | N/A |
#4 | $42.8M | 144 | 8% | N/A | N/A |
#5 | $26.5M | 98 | 4% | N/A | N/A |
#6 | $33.2M | 123 | -2% | N/A | N/A |
#7 | $29.7M | 110 | 12% | N/A | N/A |
#8 | $15.5M | 66 | -21% | $29.7M | N/A |
#9 | $1645.8M | 4354 | 13% | N/A | N/A |
#10 | $43.7M | 147 | 18% | N/A | N/A |
What Is Hibergene?
HiberGene Diagnostics is a Dublin-based, private Irish company, that develops, manufactures and markets molecular diagnostic tests for the direct detection of human infectious diseases, using the LAMP (Loop Mediated Isothermal Amplification) technology. With its expanding HG product line, HiberGene is committed to providing rapid and highly accurate testing solutions, which are cost effective and simple to use. Current HG products include molecular tests for Covid-19, Meningococcus, Group B Streptococcus (GBS), C. difficile and Mycyplasma pneumoniae. HG tests address the unmet clinical need for a rapid, highly accurate and simple testing solution, making them ideal for use in a wide range of clinical, near patient and laboratory environments.
keywords:N/AN/A
Total Funding
14
Number of Employees
$2.3M
Revenue (est)
-55%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.2M | 14 | -12% | N/A |
#2 | $1.8M | 14 | -36% | N/A |
#3 | $1.2M | 14 | -7% | N/A |
#4 | $1.2M | 14 | -18% | N/A |
#5 | $1.2M | 14 | 0% | N/A |